Work

Enterobactin and salmochelin S4 inhibit the growth of Staphylococcus aureus

Year: 2025

Type: article

Abstract: There is increasing demand for novel antimicrobial agents to tackle the antimicrobial resistance crisis. Here we report that two Enterobacteriaceae -produced siderophores, enterobactin and salmochelin S4, inhibit the growth of Staphylococcus aureus isolates, including methicillin-resistance S. aureus (MRSA) clinical isolates. The MIC 50 for different S. aureus isolates were 2-5 μM for salmochelin S4 and 5-10 μM for enterobactin. This inhibitory activity was partially repressed by adding Fe +3 . These siderophores also inhibited the growth of Enterococcus strains, including vancomycin-resistant enterococci (VRE) clinical isolates, though less effectively than for S. aureus . The growth of various Gram-negative bacteria was barely affected by these siderophores. These results shed new light on the role of enterobactin and salmochelin in bacterial physiology and ecology and have potential for the development of novel strategies to combat the rapid rise of multidrug-resistant bacteria.

Source: Frontiers in Cellular and Infection Microbiology

DOI: 10.3389/fcimb.2025.1456046

Authors: Yaacov Davidov, Noa Tejman-Yarden, Ari Robinson, Galia Rahav, Israel Nissan

Institutions: Sheba Medical Center, Israel Ministry of Health, Ariel University

Language: English

Topic: Antimicrobial Resistance in Staphylococcus

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801